Rakovina Therapeutics Valuation
| RKV Stock | CAD 0.14 0.02 16.67% |
Rakovina Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model determines the value of Rakovina Therapeutics from analyzing the company fundamentals such as Return On Equity of -0.67, shares outstanding of 90.29 M, and Price To Book of 4.11 X as well as examining its technical indicators and probability of bankruptcy.
Price Book 4.1114 | Enterprise Value 11.5 M | Enterprise Value Ebitda (3.39) |
Overvalued
Today
Please note that Rakovina Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Rakovina Therapeutics is based on 3 months time horizon. Increasing Rakovina Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Rakovina stock is determined by what a typical buyer is willing to pay for full or partial control of Rakovina Therapeutics. Since Rakovina Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Rakovina Stock. However, Rakovina Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.14 | Real 0.1 | Hype 0.15 | Naive 0.17 |
The intrinsic value of Rakovina Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Rakovina Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Rakovina Therapeutics helps investors to forecast how Rakovina stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Rakovina Therapeutics more accurately as focusing exclusively on Rakovina Therapeutics' fundamentals will not take into account other important factors: Rakovina Therapeutics Cash |
|
Rakovina Therapeutics Total Value Analysis
Rakovina Therapeutics is at this time estimated to have takeover price of 11.52 M with market capitalization of 12.64 M, debt of 1.49 M, and cash on hands of 4.37 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Rakovina Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
11.52 M | 12.64 M | 1.49 M | 4.37 M |
Rakovina Therapeutics Asset Utilization
One of the ways to look at asset utilization of Rakovina is to check how much profit was generated for every dollar of assets it reports. Rakovina Therapeutics holds a negative application of assets of -0.27 pct., losing C$0.002673 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Rakovina Therapeutics shows how discouraging it operates for each dollar spent on its assets.Rakovina Therapeutics Ownership Allocation
Rakovina Therapeutics owns a total of 90.29 Million outstanding shares. Rakovina Therapeutics has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Rakovina Therapeutics Profitability Analysis
Net Loss for the year was (2.61 M) with profit before overhead, payroll, taxes, and interest of 0.About Rakovina Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Rakovina Therapeutics. We calculate exposure to Rakovina Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Rakovina Therapeutics's related companies.Additional Tools for Rakovina Stock Analysis
When running Rakovina Therapeutics' price analysis, check to measure Rakovina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rakovina Therapeutics is operating at the current time. Most of Rakovina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rakovina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rakovina Therapeutics' price. Additionally, you may evaluate how the addition of Rakovina Therapeutics to your portfolios can decrease your overall portfolio volatility.